JP2022153418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022153418A5 JP2022153418A5 JP2022108815A JP2022108815A JP2022153418A5 JP 2022153418 A5 JP2022153418 A5 JP 2022153418A5 JP 2022108815 A JP2022108815 A JP 2022108815A JP 2022108815 A JP2022108815 A JP 2022108815A JP 2022153418 A5 JP2022153418 A5 JP 2022153418A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- hvegf
- binding fragment
- antigen
- expression cassette
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 claims 4
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 claims 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 4
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000013647 rAAV8 vector Substances 0.000 claims 4
- 230000004393 visual impairment Effects 0.000 claims 3
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 claims 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 2
- 201000004569 Blindness Diseases 0.000 claims 2
- 102000004961 Furin Human genes 0.000 claims 2
- 108090001126 Furin Proteins 0.000 claims 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 229960002833 aflibercept Drugs 0.000 claims 2
- 108010081667 aflibercept Proteins 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 238000012014 optical coherence tomography Methods 0.000 claims 2
- 229960003407 pegaptanib Drugs 0.000 claims 2
- 229960003876 ranibizumab Drugs 0.000 claims 2
- 230000003362 replicative effect Effects 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 230000004304 visual acuity Effects 0.000 claims 2
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 210000001742 aqueous humor Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 210000004127 vitreous body Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024152809A JP2025000642A (ja) | 2016-04-15 | 2024-09-05 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323285P | 2016-04-15 | 2016-04-15 | |
| US62/323,285 | 2016-04-15 | ||
| US201762442802P | 2017-01-05 | 2017-01-05 | |
| US62/442,802 | 2017-01-05 | ||
| US201762450438P | 2017-01-25 | 2017-01-25 | |
| US62/450,438 | 2017-01-25 | ||
| US201762460428P | 2017-02-17 | 2017-02-17 | |
| US62/460,428 | 2017-02-17 | ||
| PCT/US2017/027650 WO2017181021A1 (en) | 2016-04-15 | 2017-04-14 | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| JP2019505138A JP2019515027A (ja) | 2016-04-15 | 2017-04-14 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505138A Division JP2019515027A (ja) | 2016-04-15 | 2017-04-14 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024152809A Division JP2025000642A (ja) | 2016-04-15 | 2024-09-05 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022153418A JP2022153418A (ja) | 2022-10-12 |
| JP2022153418A5 true JP2022153418A5 (enExample) | 2023-02-14 |
Family
ID=60041925
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505138A Pending JP2019515027A (ja) | 2016-04-15 | 2017-04-14 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| JP2022108815A Pending JP2022153418A (ja) | 2016-04-15 | 2022-07-06 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| JP2024152809A Pending JP2025000642A (ja) | 2016-04-15 | 2024-09-05 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505138A Pending JP2019515027A (ja) | 2016-04-15 | 2017-04-14 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024152809A Pending JP2025000642A (ja) | 2016-04-15 | 2024-09-05 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20190127455A1 (enExample) |
| EP (1) | EP3442577A4 (enExample) |
| JP (3) | JP2019515027A (enExample) |
| KR (2) | KR20190003556A (enExample) |
| AU (2) | AU2017250797A1 (enExample) |
| CA (1) | CA3019665A1 (enExample) |
| IL (1) | IL262277A (enExample) |
| SG (2) | SG11201808440YA (enExample) |
| WO (1) | WO2017181021A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| MA44873A (fr) | 2016-04-15 | 2019-03-13 | Univ Pennsylvania | Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative |
| KR20200060456A (ko) * | 2017-09-27 | 2020-05-29 | 리젠엑스바이오 인크. | 완전-인간 번역후 변형된 항-VEGF Fab를 이용한 안구 질환의 치료 |
| JP2021506861A (ja) | 2017-12-19 | 2021-02-22 | アコーオス インコーポレイテッド | 内耳への治療用抗体のａａｖ媒介送達 |
| US20210093734A1 (en) * | 2018-02-20 | 2021-04-01 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-realted macular degeneration |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| BR112020025268A2 (pt) * | 2018-06-28 | 2021-03-09 | The University Of North Carolina At Chapel Hill | Cassetes de expressão e genes cln5 otimizados e seu uso |
| JP2022506613A (ja) * | 2018-11-07 | 2022-01-17 | アコーオス インコーポレイテッド | 内耳の有毛細胞及び支持細胞における遺伝子欠陥／発現タンパク質を修正するためのアデノ随伴ウイルスベクターの使用 |
| CN113966236A (zh) | 2019-04-03 | 2022-01-21 | 再生生物股份有限公司 | 眼睛病状的基因疗法 |
| BR112021021156A2 (pt) * | 2019-04-24 | 2022-02-08 | Regenxbio Inc | Terapêuticos anticorpos totalmente humanos pós-tradução modificados |
| CA3148870A1 (en) * | 2019-08-22 | 2021-02-25 | The Regents Of The University Of California | Ube3a for the treatment of angelman syndrome |
| WO2021041373A1 (en) | 2019-08-26 | 2021-03-04 | Regenxbio Inc. | Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab |
| CN114728049A (zh) | 2019-10-07 | 2022-07-08 | 再生生物股份有限公司 | 腺相关病毒载体药物组合物和方法 |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN113952474A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| JP2023544803A (ja) | 2020-10-07 | 2023-10-25 | レジェンクスバイオ インコーポレーテッド | Ｃｌｎ２疾患の眼症状に対する遺伝子療法 |
| AU2021358964A1 (en) | 2020-10-07 | 2023-05-25 | Regenxbio Inc. | Formulations for suprachoroidal administration such as formulations with aggregate formation |
| WO2022076549A1 (en) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Formulations for suprachoroidal administration such as high viscosity formulations |
| US20230414788A1 (en) | 2020-10-07 | 2023-12-28 | Regenxbio Inc. | Formulations for suprachoroidal administration such as gel formulations |
| CN116528892A (zh) * | 2020-10-28 | 2023-08-01 | 再生生物股份有限公司 | 用于眼部适应症的载体化抗TNF-α抗体 |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| CN116917491A (zh) * | 2020-12-18 | 2023-10-20 | Ac免疫有限公司 | 抗体递送 |
| EP4284335A1 (en) | 2021-02-01 | 2023-12-06 | RegenxBio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| US20250026833A1 (en) * | 2021-03-31 | 2025-01-23 | WuXi Biologics Ireland Limited | A bispecific anti-pd-l1/vegf antibody and uses thereof |
| AU2023250660A1 (en) | 2022-04-06 | 2024-10-24 | Regenxbio Inc. | Pharmaceutical composition comprising a recombinant adenoassociated virus vector with an expression cassette encoding a transgene for suprachoroidal administration |
| TW202345913A (zh) | 2022-04-06 | 2023-12-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如凝膠調配物 |
| TW202404651A (zh) | 2022-04-06 | 2024-02-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如形成聚集體之調配物 |
| IL319873A (en) | 2022-09-30 | 2025-05-01 | Regenxbio Inc | Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001029242A2 (en) * | 1999-10-21 | 2001-04-26 | Monsanto Company | Post-translational modification of recombinant proteins produced in plants |
| CN1461342A (zh) * | 2000-07-26 | 2003-12-10 | 路德维格癌症研究所 | 糖基化vegf－b和增加可溶性vegf－b量的方法 |
| PE20120622A1 (es) * | 2009-06-17 | 2012-05-26 | Abbott Biotherapeutics Corp | Anticuerpos anti-vegf y sus usos |
| US20130090375A1 (en) * | 2011-10-06 | 2013-04-11 | Cornell University | Virus-mediated delivery of bevacizumab for therapeutic applications |
| TWI775096B (zh) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| SG11201609207SA (en) * | 2014-05-13 | 2016-12-29 | Univ Pennsylvania | Compositions comprising aav expressing dual antibody constructs and uses thereof |
-
2017
- 2017-04-14 AU AU2017250797A patent/AU2017250797A1/en not_active Abandoned
- 2017-04-14 SG SG11201808440YA patent/SG11201808440YA/en unknown
- 2017-04-14 US US16/093,363 patent/US20190127455A1/en not_active Abandoned
- 2017-04-14 KR KR1020187032191A patent/KR20190003556A/ko not_active Ceased
- 2017-04-14 KR KR1020237043995A patent/KR20240005973A/ko active Pending
- 2017-04-14 JP JP2019505138A patent/JP2019515027A/ja active Pending
- 2017-04-14 SG SG10202008378UA patent/SG10202008378UA/en unknown
- 2017-04-14 CA CA3019665A patent/CA3019665A1/en active Pending
- 2017-04-14 WO PCT/US2017/027650 patent/WO2017181021A1/en not_active Ceased
- 2017-04-14 EP EP17783242.5A patent/EP3442577A4/en active Pending
-
2018
- 2018-10-10 IL IL262277A patent/IL262277A/en unknown
-
2019
- 2019-03-22 US US16/361,884 patent/US20190211091A1/en not_active Abandoned
-
2022
- 2022-03-25 US US17/704,170 patent/US20230057519A1/en not_active Abandoned
- 2022-07-06 JP JP2022108815A patent/JP2022153418A/ja active Pending
-
2024
- 2024-08-09 AU AU2024205641A patent/AU2024205641A1/en active Pending
- 2024-09-05 JP JP2024152809A patent/JP2025000642A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022153418A5 (enExample) | ||
| JP2025000642A5 (enExample) | ||
| JP2024016207A5 (enExample) | ||
| JP6355032B2 (ja) | 新規組換え二機能性融合タンパク質、それらの調製および使用 | |
| JP2024026738A (ja) | 免疫調節融合タンパク質 | |
| ES2959132T3 (es) | Nueva proteína de fusión bifuncional recombinante y preparación y aplicación de la misma | |
| US20220096596A1 (en) | Method of treating amd in patients refractory to anti-vegf therapy | |
| RU2018142768A (ru) | Варианты капсидов аденоассоциированного вируса и способы их применения | |
| CN104023748A (zh) | 含有氨基酸的蛋白质制剂 | |
| WO2002096457A2 (en) | Stable liquid formulations of antibodies | |
| EP4549459A1 (en) | Aav drug for treating angiogenesis-related fundus diseases | |
| ES2828694T3 (es) | Anticuerpos sólo de cadena pesada frente a ANG-2 | |
| KR20210153069A (ko) | 섬유아세포 성장 인자 23 관련 저인산혈증성 질환의 유전자 요법 | |
| US20220033476A1 (en) | Fusion protein of mutated single-chain human coagulation factor viii, preparation method therefor, and use thereof | |
| JPWO2019164854A5 (enExample) | ||
| JPWO2020206098A5 (enExample) | ||
| JPWO2021071835A5 (enExample) | ||
| CN102690354A (zh) | 重组二聚化抗凝血酶III-Fc融合蛋白及其哺乳动物细胞高效表达系统 | |
| WO2019219049A1 (zh) | 改进的fviii融合蛋白及其应用 | |
| JPWO2021041373A5 (enExample) | ||
| US20210277145A1 (en) | Methods and pharmaceutical compositions for increasing endogenous protein level | |
| JP2013253079A (ja) | 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用 | |
| JP2025526875A (ja) | 改善された抗アルブミンナノボディおよびその使用 | |
| US20240285800A1 (en) | Retinal Disorders | |
| TW202530256A (zh) | 多特異性抗原結合多肽之組合物及使用方法 |